FibroGen (NASDAQ:FGEN) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.15), Briefing.com reports. The firm had revenue of $29.00 million during the quarter, compared to the consensus estimate of $36.48 million. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%. The business’s quarterly revenue was down 28.6% compared to the same quarter last year.
FibroGen stock traded down $1.42 during trading hours on Friday, reaching $42.06. The stock had a trading volume of 515,088 shares, compared to its average volume of 795,988. The company has a market capitalization of $3.65 billion, a PE ratio of -24.31 and a beta of 2.15. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.95 and a current ratio of 7.95. FibroGen has a 52 week low of $38.52 and a 52 week high of $68.55.
In other FibroGen news, Director Toshinari Tamura sold 12,000 shares of the business’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $60.65, for a total value of $727,800.00. Following the completion of the transaction, the director now directly owns 63,700 shares in the company, valued at $3,863,405. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $44.32, for a total transaction of $1,756,667.52. Following the completion of the transaction, the chief executive officer now owns 2,693,250 shares of the company’s stock, valued at $119,364,840. The disclosure for this sale can be found here. Insiders sold 230,673 shares of company stock valued at $12,905,922 over the last quarter. 8.96% of the stock is currently owned by corporate insiders.
Several analysts recently weighed in on the company. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a report on Wednesday, October 17th. BidaskClub downgraded FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Mizuho restated a “buy” rating and issued a $74.00 price objective on shares of FibroGen in a report on Wednesday, August 8th. Leerink Swann set a $84.00 price objective on FibroGen and gave the company a “buy” rating in a report on Monday, October 15th. Finally, ValuEngine upgraded FibroGen from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $72.25.
TRADEMARK VIOLATION WARNING: “FibroGen (FGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.com-unik.info/2018/11/10/fibrogen-fgen-posts-quarterly-earnings-results-misses-expectations-by-0-15-eps.html.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
See Also: Why do companies engage in swaps?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.